REVIEW

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Zijun Zhao\textsuperscript{a}, Yu Chen\textsuperscript{a}, Ngiambudulu M. Francisco\textsuperscript{a}, Yuanqing Zhang\textsuperscript{b,\*}, Minhao Wu\textsuperscript{a,\*}

\textsuperscript{a}Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
\textsuperscript{b}School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

Received 13 December 2017; received in revised form 26 January 2018; accepted 18 February 2018

Abstract  Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in the treatment of hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. Solid tumors including melanoma, breast cancer and sarcoma offer great promise in CAR-T cell research and development. CD19 CAR-T cell is most commonly used, and other targets, including CD20, CD30, CD38 and CD138 are being studied. Although this novel therapy is promising, there are several disadvantages. In this review we discuss the applications of CAR-T cells in different hematological malignancies, and pave a way for future improvement on the effectiveness and persistence of these adoptive cell therapies.

© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

T lymphocyte cells (T cells) play a key role in cell-mediated immune response. These cells are involved in monitoring and killing tumor cells or potentially malignant cells. During past years many therapies have been developed to culture, redirect, and/or enhance T cells against tumors. Among them is the T cell-based adoptive immunotherapy, which is developing new means to deal with malignancies, especially hematologic cancers. This emerging therapy includes three models: tumor infiltrating lymphocytes, T cell receptor (TCR)-modified T cells and chimeric antigen receptor T cells (CAR-T cell). The first two techniques, compared with CAR-T therapy do not make a huge modification of the T cell per se, and therefore the efficacy is not substantial. Also, the process of production, the poor success rate, and the dependence upon vaccination limit their development. As a promising therapeutic regimen, CAR-T cell therapy has stood the test of time for over 25 years. Its TCR part is replaced by CAR which includes two domains: an extracellular and an intracellular domain. The extracellular domain is typically an antibody single-chain fragment (scFv) specifically against a cell surface antigen, while the intracellular domain includes fused signaling domains from a natural TCR complex and costimulatory molecules. Different intracellular sections represent various CAR-T cell generations. The structure ranges from CD3ζ signaling domain alone in first generation CARs (lack of costimulatory signal) to those that possess the signaling endo-domains of costimulatory molecules like CD28, CD134 (OX40) or CD137 (4-1BB), which are fused with CD3ζ, in second and third generation CARs. This structure imitates the costimulation signal when TCR combines with antigen-presenting cells to complete the process of activation. All of these generate CAR-T cell specificity for a certain type of cancer cell and leads to their elimination. Because a monoclonal antibody against a tumor antigen offers novel T cell specificity for certain types of cancer cells and bypasses the established antigen-presenting process, an important strength of this method is that the recognition is independent of the major histocompatibility complex. Nevertheless, a novel generation of CARs has proven attractive to scientists. In addition to costimulatory signal(s) like CD28 and (or) CD137, this so-called “fourth generation of CARs” is also equipped with a “nuclear factor of activated T cell-responsive expression” element for an inducible transgenic product like IL-12 or other cytokine (Fig. 1). The specific recognition of a carcinogenic target by CAR-CD3 signaling stimulates the nuclear factor of activated T cell minimal promoter so IL-12 production and release result. To avoid interaction between the promoter of CAR and inducible box, the two trans-genes are separated into different genomic sites. The newest version is being tested in solid tumors, but current records of clinical trials are insufficient.

The whole procedure of CAR-T cell production is complicated. Firstly, T cells from peripheral blood are collected by phlebotomy or leukapheresis, followed by apheresis without addition of granulocyte colony stimulating factor. The reason why granulocyte colony stimulating factor is excluded is that it may disrupt T-cell proliferation and responsiveness. The separated T cells then are transfected with a CAR viral (retroviral or lentiviral) or nonviral vector, where a section of genome DNA is inserted artificially. T-cell ex vivo expansion and purification is the subsequent and key step, determining the efficacy of this novel adoptive immunotherapy. The ideal dose is 1 to 5 × 10⁸ cells which, however, is not equal to the CAR-T cell count in human bodies. Finally, tests of cell quality and sterility are necessary, which take 2-4 weeks to complete. Before the transduced T cells are administered a conditioning treatment, including lymphodepleting, should be done 2 days ahead for a greater T cell expansion.

This kind of immunotherapy is commonly used in hematological malignancies such as acute lymphoblastic leukemia (ALL).
chronic lymphocytic leukemia (CLL), lymphoma, and multiple myeloma (MM). The most common target is CD19 and the total response is optimistic for ALL. Other targets such as CD20, CD30, CD138 are showing some success as well. Solid tumors are becoming another battleground for CAR-T cell regimens, including melanoma, sarcoma and breast cancer. Contrary to hematologic tumors, the majority of treatment in solid tumors is unsuccessful due to insufficient and atypical molecular targets for CAR-T cells to attack and control the microenvironment of tumor. Despite many issues about safety and efficacy, this technique is indisputably a promising tool for the future adoptive cancer immunotherapy. Here, we provide a framework mainly for understanding the applications of CAR-T cells in different hematological cancers, and also discuss future directions that will undoubtedly inform the improvement of the effectiveness of these adoptive cell therapies.

2. Applications of CAR-T cells in various hematological malignancies

2.1. CAR-T cell in acute lymphoblastic leukemia and chronic lymphocytic leukemia

2.1.1. CAR-T cell therapy in acute lymphoblastic leukemia

So far treatment of ALL, especially fatal relapsed/refractory (r/r) B-ALL is the most suitable for CAR-T therapy. During the treatment of ALL, the most effective CAR is anti-CD19, an essential biomarker of B cell lineage showing higher expression in B-ALL, while anti-CD20 and immunoglobulin light chains are also potential targets. The first generation of CAR incorporated only a CD3ζ chain and failed to generate potent antitumor effects with relatively short persistence. This prompted scientists to upgrade, triggering the creation of the second generation of CAR. Despite a better efficacy of the second generation CAR-T cell with either CD28 or 4-1BB, combining them might be a superior choice, which may give rise to a third generation of CAR-T cell.

Studies have reported data from clinical trials with CD19-targeted CAR-T cells for adults and children inflicted by r/r B-ALL. All showed promising complete remission (CR) and partial remission (PR) rates. In one clinical study, following conditioning therapy (cyclophosphamide), CD19 CAR-T cells were infused, and 15 out of 16 patients required a qualified amount of T cells; the CR rate was 88%. Delightfully, the CR was of high quality as few detectable disease indicators were detected by high-sensitive molecular assays such as deep-sequencing or real-time polymerase chain reaction. Studies involving children and young adult patients (aged 1–30 years old) have found that the CR rate for the 20 B-ALL patients was 70% and the molecular CR rate was 60%. The limited persistence of CAR-T cells (approximately 2 months) is counterbalanced by the rapid remission of patients and post-treatment allogeneic stem-cell transplant. In another clinical trial, patients received conditioning treatment, including both fludarabine and cyclophosphamide completed 1 week ahead of adoptive transfer of CAR-T cells. The CR rate was 90% and the molecular CR rate was 73%. Other research teams have also carried out clinical studies of ALL.

In addition, some studies have suggested that the defined composition of CD4+ and CD8+ CAR-T cell in one intravenous infusion can reveal factors that facilitate the evaluation of efficacy, adverse effects, cell expansion and the persistence of mixed products. This is important for additional therapies such as lymphodepletion and anti-tumor drug use, which may clarify the relationship between CAR-T cell dose, cell expansion in vivo and the toxicity risk in order to adjust infusing dose to reduce the possibility of cytokines release syndrome (CRS) and neurotoxicity. Although CD19 is an ideal target for CAR-T cell treatment in ALL, studies have found that “antigen escape” is a potential obstacle in the development of immunotherapy, thereby making it imperative to optimize, including recognition and identification of additional targets. Fortunately, CD22 is another potential target for CAR-T cell, and recently, two different anti-CD22 agents have been tested against B-ALL in clinical trials to make up the deficiency of anti-CD19 therapy.
Table 1  
Selected clinical trials of CAR-T cell therapy in ALL.

| Institute                                      | CAR (target & generation) | Sample Number (M/F) Age | Effective No. of participants | Outcome and Ref. |
|------------------------------------------------|---------------------------|-------------------------|--------------------------------|-------------------|
| Memorial Sloan-Kettering Cancer Center         | CD19 2nd CD28             | 16 (12/4) Adult         | 15e                            | CR rate: 88%      |
| Fred Hutchinson Cancer Research Center         | CD19 2nd 4-1BB            | 29                     | Not available                   | CR rate: 93%      |
| National Cancer Institute                      | CD19 2nd CD28             | 21d (14/7) 14.71 ± 6.64 | 21                             | CR rate: 66.7%    |
| University of Pennsylvania                     | CD19 2nd 4-1BB            | 30 (18/12) Children & Adult | 30                             | CR rate: 90%      |
| University of Pennsylvania                     | CD19 2nd 4-1BB            | 27                     | Adult                          | 3 CR in cohort 1 and 2; 3 CR in cohort 3; 75% CR and 8.3% PR in cohort 4 | |
| Hebei Yanda Lu Duopei Hospital                 | CD19 2nd 4-1BB            | 42 (28/14)e Children & adult | 40f                            | CR rate: 90%      |
| Peking University People's Hospital            | CD19 4th (CD28/4-1BB/CD27/inducible apoptotic caspase9 | 6 (1/5) 26.50 ± 13.62 | 5g                            | 5 achieved minimal residual disease (MRD)-negative remission |

Abbreviations: aGVHD, acute Graft-versus-host disease; ALL, acute lymphoblastic leukemia; BM, bone marrow; CAR T cell, chimeric antigen receptor T cell; CR, complete remission; M/F, male and female; MRD, minimal residual disease; PR, partial remission; Ref, reference; SEM, standard error of mean.

The denominator in the calculation is the total sample number. One patient had only gross extramedullary disease (no detectable disease in the BM). No gender indicated. Twenty ALL patients. This clinical trial has two groups: one includes 42 primary refractory/hematological relapsed and 9 refractory minimal residual disease (MRD) by flow cytometry B-ALL patients. Two patients died from treatment-related mortality early in the trial (on days 21 and 24). One patient was discharged automatically without evaluation after developing severe thrombotic microangiopathies. Four of five responsive patients relapsed after 2–7 months, and one died of sepsis following MRD-negative remission after a second infusion. None of the other second infusion recipients achieved a second complete remission. Two and one patient developed grade 2 and 3 aGVHD, respectively. Ages of patients are expressed as mean ± SEM if the data are available.

Table 2  
Selected clinical trials of CAR-T cell therapy in CLL.

| Institute                                      | CAR (target & generation) | Sample Number (M/F) Age | Effective No. of participants | Outcome and Ref. |
|------------------------------------------------|---------------------------|-------------------------|--------------------------------|-------------------|
| University of Pennsylvania                     | CD19 2nd 4-1BB            | 14 (12/2) 66.90 ± 8.10 | 14                             | CR rate: 28%; PR rate: 28% |
| University of Pennsylvania                     | CD19 2nd 4-1BB            | 30                     | Adult                          | CR rate: 22%; PR rate: 17% |
| National Cancer Institute                      | CD19 2nd CD28             | 15d (8/7) 51.67 ± 11.22 | 15d                            | CR rate: 53%      |
| Memorial Sloan Kettering Cancer Center         | CD19 2nd CD28             | 10d (8/2) 63.90 ± 8.49 | 9d                             | No CR             |
| National Cancer Institute                      | CD19 2nd CD28             | 20 (11/9) 50.93 ± 12.86 | 20d                            | CR rate: 30%; PR rate: 10%, no aGVHD by CAR-T cell infusion |
| Fred Hutchinson Cancer Research Center         | CD19 3rd CD28/4-1BB       | 24b                     | 59.54 ± 7.87                    | CR rate: 16.7%; PR rate: 54.2% |

Abbreviations: aGVHD, acute Graft-versus-host disease; ALL, acute lymphoblastic leukemia; CAR-T cell, chimeric antigen receptor T cell; CLL, chronic lymphocytic leukemia; CR, complete remission; M/F, male and female; PR, partial remission; Ref, reference; SEM, standard error of mean.

One patient (ALL) was yet to be treated with modified T cells. The denominator in the calculation is the total sample number. One died after 21 months post-treatment period. Only one is alive with disease. Including 4 CLL patients. There were 8 CLL patients. There are 5 CLL patients. No gender indicated. Ages of patients are expressed as mean ± SEM if the data are available.
2.1.2. CAR-T cells therapy in chronic lymphocytic leukemia

CLL is a chronic malignancy with a varying clinical course and prognosis for chemotherapy. However, the only current approach to curing CLL is allogeneic stem-cell transplantation. Recently, CD19 CAR-T cells were used to treat patients with relapsed and risky CLL and some response to the CAR-T cell in CLL patients with equal CR and PR rate have been reported. In addition to CD19, several other targets such as the tyrosine-protein kinase trans-membrane receptor have been explored. In the past several years several studies have explored the effect of CAR-T cells in CLL patients.

Because CLL pathogenesis leads to early immune deficiency, the efficacy of CAR-T cell therapy will be limited by difficulties in expansion of T cells ex vivo from CLL patients and their proliferative response in vivo. Finding agents that enhance the ability to prevent the above phenomenon is of necessity. Ibrutinib, an irreversible inhibitor of bruton tyrosine kinase, may not only avoid negative effects on the T cell but could also improve its antitumor capability. To test the effect of ibrutinib on the T cell in CLL patients, Fraietta et al. tested the phenotype and function of T cells in a cohort study of CLL patients during their treatment course with ibrutinib. The result showed that five cycles of ibrutinib therapy enhanced the expansion of CD19-directed CAR-T cells (CTL019, a second-generation of CD19 CAR-T cell), and decreased the expression of programmed cell death protein 1 (an immunosuppressive molecule) on T cells; and increased the expression of CD200, a tetra-trans-membrane protein presents in more than 90% of CLL patients and their cells. CD200 receptor is important to regulate molecule) on T cells; and increased the expression of CD200 receptor and CD200 receptor has been shown to increase antitumor immunity.

2.2. CAR-T cell therapy in lymphoma

Patients with disease deterioration after primary and secondary therapies for lymphoma have been found to have a poor prognosis even though they have shown improvements in cytotoxic chemotherapy regimens and monoclonal antibody therapies. However, there is a novel and effective treatment alternative for patients who have shown no resolution after multiple lines of chemotherapy. CAR-T cells are among the latest advanced immunotherapies for relapsed or chemotherapy-refractory B-cell non-Hodgkin lymphoma (NHL).

There are several types of CARs modified on the surface of T cells either autonomously or allogeneically, and the anti-CD19 CAR-T cell is the earliest and the most traditional. For lymphoma, the first-generation of CAR-T cells were not effective in preventing proliferation, persistence and homing compared to the second and third generation. Two different studies have reported preclinical results showing superior proliferative and antitumor activities of the second and third generation T cells, with the CD28 or 4-1BB cytoplasmic signaling domains, both in vitro and in vivo. Despite a positive effect of CD28 as an early signal in improving cell expansion and persistence, some trials have suggested that using CAR containing 4-1BB as a late costimulatory signal yields more remarkable expansion and anti-tumor activity in indolent B cell malignancies. For example, CTL019 therapy has shown great effect in some patients with advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Among 8 eligible patients, 4 people had responses at different levels: 3 CRs (CR rate is 13%) and 1 PR (PR rate is 4%), with a 50% 3-month overall response rate. Four patients with DLBCL had progressive disease before or at initial response assessment, and there was no treatment-related mortality.

The longest ongoing clinical response in this study was more than 350 days for FL, and 400 days for DLBCL. CD28-containing CAR-T cells have continued to show promise for patients. For instance, studies have shown that 75% of patients who suffered from splenic marginal zone lymphoma achieved PR, and this was also shown in other corroborative studies. These patients were all maintained for several months (ranging from 7 to over 18 months).

Besides CD19, other surface biomarkers are also essential. CD20, a tetra-trans-membrane protein presents in more than 90% of B-cell lymphomas and is a well-established target for NHL treatment. Currently, first-generation anti-CD20 CAR-T cell therapy has been used in several studies. In one clinical trial 7 participants suffering from lymphomas were treated. Two patients in this study achieved CR, 1 subject got a PR while the disease in another 4 patients was stable. To test whether the second-generation of CAR-T treatment is effective in DLBCL patients, a study in 2014 using anti-CD20 CAR-T cell with 4-1BB reported a promising effect of this novel treatment.

In this study, 7 patients with refractory advanced DLBCL were recruited. Among them, 5 patients were burdened with bulky tumors and the other 2 were not. Except for 1 subject, the other 6 patients received preconditioning chemotherapy for disease control or the tumor was debulked before anti-CD20 CAR-T cell infusion. One of the two patients without a bulky tumor burden achieved a 14-month long lasting and ongoing CR without preconditioning regimen, and another gained a 6-month tumor regression. 3 of 5 with bulky tumors got 3- to 6-month tumor regression.

CD30, another potential target, is a member of the TNFR superfamily. It is an antigen to the Ki-1 antibody which binds to Reed-Sternberg cells in Hodgkin lymphoma (HL). CD30-positive lymphocytes are mainly found around the follicular areas of lymphoid tissues, but is less common in germinal centers. For lymphoma, CD30 is expressed in classical HL,
anaplastic large cell lymphoma, DLBCL, primary mediastinal B-cell lymphoma, and peripheral T-cell lymphoma. Recently, Wang et al. reported that 18 patients with r/r HL, who received a conditioning chemotherapy prior to the CD30 CAR-T cell infusion showed progression in regard to their conditions before CAR-T cell infusion. Almost 7 patients achieved PR and 6 maintained stable disease (SD). In all these patients their lymph node lesions responded better than extra-nodal lesions, and the response in lung lesions seemed to be relatively poor. Analysis of biopsy tissues by real-time quantitative polymerase chain reaction and immunohistochemistry revealed CAR-T cells migrating into the targeted sites, and reduction in the expression of CD30 in tumors. Moreover, introduction of EBV-specific CAR-T cells that recognize and kill Epstein-Barr virus (EBV)-infected cells may secure against the relapse of EBV-related B-cell NHLs, including BL and DLBCL.

In regard to κ-light chain, it is a feasible choice for B-cell lymphoma in that mature malignant B cells express either a κ or λ light immunoglobulin chain. Anti-κ/λ CAR-T cells, hence, can target one kind of malignant B cell and avoid damaging normal B cells. In one dose-escalation study, 10 r/r κ+ NHL, or CLL patients were infused with autologous CAR-κ T cells and any other treatments were discontinued at least 4 weeks ahead of T-cell infusion. This study reported that among the 5 NHL patients, 2 entered CR (after 2 and 3 infusions at dose level 1 and 3, respectively), 1 patient achieved PR, and 2 other subjects progressed. The clinical trials aforementioned are summarized in Table 3.

2.3. CAR-T cell in multiple myeloma

Multiple myeloma (MM) is a bone-marrow-derived refractory malignancy leading to anemia, immunosuppression with repeated infections, hypercalcemia, bone lesions and renal failure. Despite chemotherapy, autologous hematopoietic stem cell transplantation or the use of other immune-modulatory agents, this disease remains incurable because of the heterogeneous cytogenetic and molecular abnormalities of myeloma. However, the fact that myeloma can subside as a result of the graft-versus-myeloma effect in allogeneic stem cell transplantation provides insight into the role of T-cell-based immunotherapy. Studies have found a lower, but a more frequent expression of CD19 on myeloma cells. Because myeloma cells hardly express CD19 on their surface, anti-CD19 CAR-T cells cannot perform well to kill the malignant cells; instead, they harm some healthy tissues other than tumors. Two studies targeted this population via the use of CTL019 cells, reporting a remission in a 43-year-old patient with 9 prior lines of treatment with nearly no sign of CRS. It is therefore evident that more specific targets presented on tumor cells versus those on non-vital, healthy tissues should be explored to achieve a broader application in MM.

Another molecule involved in this event is CD138, which is a membrane protein and belongs to the Syndecan family of heparan sulfate proteoglycans. In hematopoietic tissues, malignant and differentiated plasma cells express this biomarker. It is also present in neoplastic, mature epithelial cells and other normal tissues. By virtue of its expression in nearly all MM patients, CD138 is used as a primary diagnostic marker. The result of a clinical trial using second-generation of anti-CD138 CAR-T cell treatment of 5 refractory MM subjects showed that, after 7-month follow-up treatment, the conditions of at least 4 patients were stable and one patient with advanced plasma cell leukemia had a reduction of myeloma cells in peripheral blood. This shows that the CAR-T cells had entered the bone marrow. Thus, CD138 CAR-T cell therapy for MM is well-tolerated and potentially has anti-tumor immunity.

B-cell maturation antigen (BCMA, CD269) is another molecule that has been identified and is a promising immunotherapeutic target in MM. Expressed only in lymphoid tissue of healthy individuals and on mature B cells or plasma cells, BCMA enhances the survival of long-lived plasma cells in MM patients. Patients that were recently enrolled in an anti-BCMA/CD269 CAR-T cell treatment in MM received CAR-BCMA T cells in a dose-escalation trial. In addition, this study reported that all patients were pretreated with cyclophosphamide and fludarabine to enhance the activity of adoptive transferred T cells as previously reported. In these 6 patients treated at the lowest 2 dose levels, low anti-myeloma activity or toxicity was noticed. Moreover, at the third dose level 1 patient obtained a very-good PR. Furthermore, two chemotherapy-resistant patients were treated on the fourth dose level with anti-BCMA CAR-T and achieved stringent CR lasting for 17 weeks before relapse. Ongoing promising PR corroborative studies have also shown a similar therapeutic outcome. The above mentioned studies and the 2 corroborative studies are further summarized Table 4. Some bench studies have brought exciting stories of new approaches to treat MM, and progress have been achieved in vivo and hopefully further experimental and clinical trials will usher in a new era of MM immunotherapy.

3. Advantages and disadvantages in the application of CAR-T cell therapy in hematological malignancies

3.1. Advantages of CAR-T cell therapy in hematological malignancies

In contrast with common adaptive immune cells, CAR-T cells have unique specificity and can eliminate cancer cells containing the corresponding TAAs. To some extent this technique will avoid unnecessary killing of healthy tissues. Furthermore, CAR-T cells can recognize cell surface molecules without the help of HLA expression. Its advantage over the former one is that tumors often avoid T cell immune surveillance by hiding HLA or other molecules involved in antigen processing and presentation. In addition, the flexibility of intracellular signaling domains within CARs permits the cell to counteract the downregulation of co-stimulatory molecules directly or indirectly caused by cancer cells. It is worthwhile to mention that CAR-T cell can recognize potential antigens in nearly all forms including carbohydrate, lipid, protein antigens, which can be combined specifically by antibodies.

3.2. Disadvantages of CAR-T cell therapy in hematological malignancies

When treating hematological malignancies using CAR-T cells, it turns out that activating the antitumor immunity of engineered T cell results in broad and strong cytokine-driven effects, including CRS, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis. Among them, CRS is a clinical response to raise cytokine levels and includes symptoms such as hypotension,
Table 3  Selected clinical trials of CAR-T cell therapy in lymphoma.  

| Institute | CAR (target & generation) | Sample Effective No. of participants | Outcome | Publishing year & Ref. |
|-----------|---------------------------|--------------------------------------|---------|------------------------|
|           |                           | Number (M/F) Age                      |         |                        |
| University of Pennsylvania | CD19 2nd 4-1BB | 23 (14/9) Adult | 20<sup>a</sup> | CR rate: 13%; PR rate: 4%; 2014<sup>45,78</sup> |
| National Cancer Institute | CD19 2nd CD28 | 8<sup>b</sup> 55.88 ± 5.77 8<sup>c</sup> | 5 PRs; 1 CR; 1 SD<sup>d</sup> 2012<sup>46,77</sup> |
| National Cancer Institute | CD19 2nd CD28 | 15<sup>e</sup> (8/7) 51.67 ± 11.22 15<sup>e</sup> | CR rate: 53%; PR rate: 26%; SD rate: 7% 2014<sup>74</sup> |
| National Cancer Institute | CD19 2nd CD28 | 9 (8/1) Adult 9 | 1 CR<sup>e</sup>; 5 PRs<sup>e</sup> 2014<sup>74</sup> |
| Fred Hutchinson Cancer Research Center & National Cancer Institute | CD20 1st CD3z | 9 (8/1) Adult 7<sup>f</sup> | 2 CRs<sup>e</sup>; 1 PR<sup>e</sup>; 4SDs<sup>e</sup> 2008<sup>43</sup> |
| Fred Hutchinson Cancer Research Center | CD19 (the generation is unknown) | 28<sup>g,h</sup> Adult 24<sup>i</sup> | In 12 patients received lymphodepletion with Cy-based regimens without fludarabine, the CR rate is 8.3% and PR rate is 41.7%; In 16 patients received lymphodepletion with addition of fludarabine, the CR rate is 42% and PR rate is 25% 2015<sup>79</sup> |
| Chinese PLA General Hospital | CD20 2nd 4-1BB | 7 (6/1) 65 | 4SD<sup>a</sup> 2015<sup>24</sup> |
| National Cancer Institute | BCMA 2nd CD28 | 12<sup>d</sup> | 1PR and 2 SD in group of “0.3 × 10<sup>6</sup>/kg CAR-T cell”; 3 SD in group of “1 × 10<sup>6</sup>/kg CAR-T cell”; 1CR, 1 PR and 1 SD in group of “9 × 10<sup>6</sup>/kg CAR-T cell” 2016<sup>105</sup> |
| Chinese PLA General Hospital | CD30 2nd 4-1BB | 18 (13/5) 31 | PR rate: 39%; SD rate: 33% 2016<sup>109</sup> |
| Baylor College of Medicine | κ-Lightchain | 13<sup>k</sup> Not available 10 | CR rate: 15%; PR rate: 30% 2013<sup>14</sup> |

Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete remission; M/F, male and female; PD, progress disease; PR, partial remission; Ref, reference; SD, stable disease; SEM, standard error of mean.

<sup>a</sup>The denominator in the calculation is the total sample number. <sup>b</sup>Three patients were removed from the trial before therapy due to progressive disease. <sup>c</sup>There are 5 lymphoma patients. <sup>d</sup>No gender indicated. <sup>e</sup>In this study, we use the absolute value instead of rate in that the response rate is meaningless (sample size is less than 10). <sup>f</sup>There are 11 lymphoma patients. <sup>g</sup>The reason why 2 of nine patients was untreated is unknown. <sup>h</sup>In this clinical trial, there are two main groups, one is non-Hodgkin lymphoma and the other one is chronic lymphacytic leukemia. <sup>i</sup>Four patients were not available, among which 2 died early. <sup>j</sup>One participant died of severe hemorrhage of the alimentary tract. <sup>k</sup>Ages of patients are expressed as mean ± SEM if the data are available.

Table 4  Selected clinical trials of CAR-T cell therapy in multiple myeloma.  

| Institute | CAR (target & generation) | Sample size Effective No. of participants | Outcome | Publishing year & Ref. |
|-----------|---------------------------|--------------------------------------|---------|------------------------|
|           |                           | Number (M/F) Age                      |         |                        |
| Chinese PLA General Hospital | CD138 2nd 4-1BB | 5(1/4) Adult | 5<sup>a</sup> | 4SD<sup>a</sup> 2015<sup>24</sup> |
| National Cancer Institute | BCMA 2nd CD28 | 12<sup>d</sup> Not available 12 | 1PR and 2 SD in group of “0.3 × 10<sup>6</sup>/kg CAR-T cell”; 3 SD in group of “1 × 10<sup>6</sup>/kg CAR-T cell”; 1CR, 1 PR and 1 SD in group of “9 × 10<sup>6</sup>/kg CAR-T cell” 2016<sup>105</sup> |
| Bluebird Bio<sup>l</sup> | BCMA 2nd 4-1BB (bb2121) | 9<sup>i</sup> Not available 9 | 2CRs in a cohort of 15×10<sup>7</sup> CAR-T cells; 1 PR in a cohort of 5.0×10<sup>7</sup> CAR-T cell, 1 PR in the cohort of 15×10<sup>7</sup> CAR-T cells and 2 PR in a cohort of 45×10<sup>7</sup> CAR-T cell; 1 SD in the cohort of 5.0×10<sup>7</sup> CAR-T cell and another one is in the cohort of 45×10<sup>7</sup> CAR-T cell 2017<sup>109</sup> |
| University of Pennsylvania | BCMA 2nd 4-1BB | 11<sup>d</sup> Not available 6<sup>i</sup> | 1CR ;1PR ;1 SD 2016<sup>100</sup> |

Abbreviations: BCMA, B cell maturation antigen; CAR-T cell, chimeric antigen receptor T cell; CR, complete remission; M/F, male and female; PD, partial remission; Ref, reference; SD, stable disease.

<sup>a</sup>In this study, we use the absolute value instead of rate in that the response rate is meaningless (sample size is less than 10). <sup>b</sup>One patient only accepted the dose of 3 × 10<sup>6</sup>/kg CAR-T cell. <sup>c</sup>Five patients not receiving treatment because of screen fail (n = 2), rapid multiple myeloma progression/renal failure (n = 2), and self choice (n = 1). <sup>d</sup>No gender indicated. <sup>e</sup>Ages of patients are expressed as mean ± SEM if the data are available.
fevers, neurological changes and hypoxia\textsuperscript{52,56,77,116}. Risk-adapted CAR-T cell dosing strategies have been carried out in response to the greater incidence of severe CRS observed among patients who showed greater baseline disease burden, and were treated with higher doses of CAR-T cells\textsuperscript{21,41,117}. Systemic corticosteroids are used as first-aid treatment for patients with life-threatening CRS to lessen or even eliminate the hyper-proliferative activated CAR-T cells. But the downside has been revealed as well: rapid ablation of engineered T cells will depress the antitumor efficacy of CD19 CAR-T cells and trigger subsequent disease progression or relapse\textsuperscript{30,49,118}. The investigation of cytokines in several studies surprisingly identified IL-6 as a major cytokine induced by CAR therapy. Meanwhile, IL-6 also stems from apoptotic B cells or activated macrophages and moves to lysed tumor cells \textit{via} chemotaxis\textsuperscript{11}. Thus, the anti-IL-6 receptor antagonist antibody tocilizumab was successfully designated to weaken the cytokine-induced side effect, a treatment now being applied more systematically to counteract cytokine-release syndrome\textsuperscript{33,39}.

Neurotoxicity is another serious potential toxicity arising from CAR-T cell therapy and has been observed in several patients treated with CD19 CAR-T cells\textsuperscript{119}. Symptoms of neurotoxicity include visual hallucinations, delirium, dysphasia, epilepsy or seizure\textsuperscript{120}. Endothelial dysfunction, including vascular instability, capillary leak, blood-brain barrier disruption and disseminated intravascular coagulation are clinical evidence of neurotoxicity\textsuperscript{121}. For medical imaging results, an abnormal brain MRI scan can suggest neurotoxicity by showing vasogenic edema, leptomeningeal enhancement, and/or multifocal microhemorrhages\textsuperscript{121}. Similar to CRS, IL6, IFN-\(\gamma\) and TNF are prime culprits in inducing acute neurotoxicity so treatment can also apply tocilizumab to suppress IL6-mediated inflammatory pathways\textsuperscript{121}.

Although CAR-T cell has relative specificity as noted above, every regimen may result in tissue damage at different levels because the molecular biomarkers can be expressed in some normal tissues or organs, especially the lymphatic tissues. This phenomenon is referred to as on-target/off–tumor toxicity, which includes B cell aplasia in anti-CD19/CD20 CAR-T cell treatment\textsuperscript{20,77,122}. Also, antigen escape, typically CD19-negative relapse of B cell malignancy, may challenge the success rate of CARs in blood cancer\textsuperscript{17,20,21,41}.

### 4. Outlook

CAR-T cell therapy has made great progress in recent decades, however, several challenges still need to be solved. The main issues are how to improve the effectiveness and persistence of adoptive cells and to reduce the adverse effects of treatment.

On one hand, to improve the treatment effect, CAR-T cells can be further equipped to improve their effectiveness and persistence by adding new co-stimulatory domains or CAR parts\textsuperscript{123}. Since glucocorticoid-inducible tumor necrosis factor receptor-related...
protein (GITR, CD357) and 4-1BB are both nuclear factor-κB (NF-κB)-inducing members of the TNFR family and GITR is a costimulatory molecule, we suggest that further research is needed on the effect of adding this domain, and combining them with CD28 and 4-1BB to evaluate the effect of T-cells. Plus, reconstructing the CAR part is a new approach to antigen escape or coexistence of multiple tumor antigens in lymphoma, MM and other type of malignancies. Bi-specific CAR-T cell is a promising treatment and it includes two formations: First, one CAR is composed of two different scFvs “hand-in-hand” (TanCAR) (Fig. 3) or two distinct CARs with different scFvs on one single T cell (dual-signaling CAR)125,126; second, T cell pools with different typical CARs infused sequentially or simultaneously127. Nevertheless, challenges still exist in recognizing the coexisting targets on a tumor cell and selecting the proper epitope in TanCAR therapy128,129. In addition, oncolytic viruses can infect the host, replicate and damage certain tumor cells without harming normal cells130,131. Evidence has shown that tumor cells can be killed via the new viral proteins integrated in its cytoplasm presented by the major histocompatibility complex class I molecules, and thereafter being recognized and destroyed by CD8+ T cells130. In addition, tumor cells can also be killed by the release of progeny viral particles130 (Fig. 4). Applications for this type of tumor cell killing viruses such as Myxoma virus, adenovirus serotype 5 and Coxackievirus A21 have been reported in MM132–134. B- and T-lymphoma or leukemia-derived cells/xenografts have also been used as preclinical models135–137. Studies have reported the use of oncolytic virus equipped with chemokine genes to recruit CAR-T cells, prolong their persistence and directly attack tumor cells138,139. This is a promising approach which can be tested during hematological malignancies.

On the other hand, avoiding uncontrolled T cell proliferation, cytokine storm, or “on-target/off-tumor” effects during CAR-T cell treatment is essential. Some researchers suggest that suicide-gene (also known as “elimination genes”) systems can be activated to destroy infused CAR-T cells to regulate the expansion of CAR-T cells and restrict toxicity132,140. To date, some methods have been proved: suicide gene therapy with the Herpes simplex thymidine kinase/ganciclovir suicide system in the context of allo-HSCT has shown its safety and effectiveness141, and other non-immunogenic suicide systems have been developed, especially through a modified caspase-9 member of the intrinsic apoptosis pathway. A new version of FK506-binding protein, demonstrating a propyl isomerase activity has been combined with caspase-9142,143. However, such suicide strategy will shorten the duration of treatment by thoroughly eliminating CAR-T cell143. Switchable CAR-T cell can make up this defect by inserting a small molecular complex between the scFv and T cell surface to “turn on” the cell function and discontinue adding it to switch off144. Another way to switch the cell between “on and off” would be to engineer a soluble intercellular molecule that contains a tumor antigen-specific antibody, a secondary moiyet binding to CARs. This structure allows the researcher to switch the cell function by changing the concentration of the intermediary molecules. This novel format is being tested145.

5. Conclusions

CAR-T cell therapy has made great progress to deal with hematological malignancies, especially ALL, CLL and lymphoma while the effectiveness, cell persistence and adverse effects become bottlenecks to the widespread use of this approach. Innovative bench research is required to strengthen the effectiveness of this therapy; that will give physicians and patients the information and therapeutics to eliminate these malignancies.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (Nos. 31670880 and 31370868), the Guangdong Natural Science Fund for Distinguished Young Scholars (No. 2016A030360004), Guangdong Special Support Program for Youth Science and Technology Innovation Talents (No. 2015TQ01R473), Guangzhou Pearl River New Star Program (No. 201610010064), Guangdong Innovative Research Team Program (No. 2011Y035).

References

1. Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 2015;3:1115–22.
2. Barrett DM, Grupp SA, June CH. Chimeric antigen receptor-and TCR-modified T cells enter main street and wall street. J Immunol 2015;195:755–61.
3. Fujiwara H. Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals 2014;7:1049–68.
4. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013;4:371.
5. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989;86:10024–8.
6. Enblad G, Karlsson H, Loskog AS. CAR-T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther 2015;26:498–505.
7. Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett 2016;370:85–90.
8. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol 2015;36:494–502.
9. Advani A. Antibodies: immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2015;28:116–23.
10. Doyle C. CAR-T cells: the transplants of the future. Am Health Drug Benefits 2015;8:14.
11. Lorentzen CL, Straten PT. CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Scand J Immunol 2015;82:307–19.
12. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 2015;15:11145–54.
13. Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther 2015;22:79–84.
14. Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist 2016;21:608–17.
15. Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4+ T cells. Blood 1998;91:347–52.
16. Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Chimeric antigen receptor T cells in hematologic malignancies. Pharmacotherapy 2017;37:334–45.
17. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase I dose-escalation trial. Lancet 2015;385:517–28.
18. Porter DL, Frey NV, Melenhorst JJ, Hwang WT, Lacey SF, Shaw P, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. *Blood* 2014;124:1982.

19. Landoni E, Savolbo B. Treating hematological malignancies with cell therapy: where are we now?. *Expert Opin Biol Ther* 2018;18:65–75.

20. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* 2014;371:1507–17.

21. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients. *J Clin Invest* 2016;126:2123–38.

22. Chen F, Fan C, Gu X, Zhang H, Liu Q, Gao X, et al. Construction of anti-CD20 single-chain antibody-CD28-CD137-TCR, ε recombinant genetic modified T cells and its treatment effect on B cell lymphoma. *Med Sci Monit* 2015;21:2110–5.

23. Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. *Clin Cancer Res* 2017;23:1156–66.

24. Guo B, Chen M, Han Q, Hui F, Dai H, Zhang W, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. *J Cell Immunother* 2016;2:28–35.

25. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR-T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. *Mol Ther* 2016;24:1135–49.

26. Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. *Cancer Immunol Res* 2017;5:1152–61.

27. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of her2-positive sarcoma. *J Clin Oncol* 2015;33:1688–96.

28. Kakarla S, Gottschalk S. CAR-T cells for solid tumors: armed and ready to go?. *Cancer J* 2014;20:151–5.

29. Lamers CH, Sleijfer S, Van Steenbergen S, Van Elzakker P, Van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. *Mol Ther* 2013;21:904–12.

30. Hillerdal V, Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. *BioDrugs* 2015;29:75–89.

31. You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, et al. Phase I clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells. *Sci China Life Sci* 2016;59:386–97.

32. Davila ML, Sadelain M. Biological and clinical application of CAR-T cells for B cell malignancies. *Int J Hematol* 2016;104:6–17.

33. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. *Annu Rev Immunol* 2014;32:189–225.

34. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. *Blood Rev* 2016;30:157–67.

35. Ruella M, Kalos M. Adoptive immunotherapy for cancer. *Immunol Rev* 2014;257:14–38.

36. Jain N, O’Brien S. Targeted therapies for CLL: practical issues with the changing treatment paradigm. *Blood* 2016;30:233–44.

37. Shalabi H, Angiolillo A, Fry TJ. Beyond CD19: opportunities for future development of targeted immunotherapy in pediatric relapsed/refractory acute leukemia. *Front Pediatr* 2015;3:80.

38. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin Cancer Res* 2006;12:6106–15.

39. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* 2014;6:228ra25.

40. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013;5:177ra38.

41. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–18.

42. Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. *Leukemia* 2017;31:2587–93.

43. Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). *J Clin Oncol* 2016;34:7002.

44. Sommermeyer D, Hudecek M, Kosashl PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8⁺ and CD4⁺ subsets confer superior antitumor reactivity in vivo. *Leukemia* 2016;30:492–500.

45. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR-T cells of defined formulation and dose in children and young adults. *Blood* 2017;129:3322–31.

46. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR. Generation of CD19-chimeric antigen receptor modified CD8⁺ T cells derived from virus-specific central memory T cells. *Blood* 2012;119:72–82.

47. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8⁺ T cells in immunodeficient mice. *Blood* 2011;117:1888–98.

48. Turtle CJ, Riddell SR, Maloney DG. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. *Clin Pharmacol Ther* 2016;100:252–8.

49. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. *Cancer J* 2014;20:119–22.

50. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. *Cancer Immunol Res* 2016;4:498–508.

51. Mewawalla P, Nathan S. Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. *Ther Adv Hematol* 2014;5:139–52.

52. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med* 2011;3:95ra73.

53. Kochenderfer JD, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol* 2015;33:540–9.

54. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefaniski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* 2011;118:4817–28.

55. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med* 2015;7:303ra139.
The application of CAR-T cell therapy in hematological malignancies

Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725–33.

Pavletic SZ, Kumar S, Mohty M, De Lima M, Foran JM, Pasquini K, et al. Brutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood* 2016;127:1117–27.

Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. *Leukemia* 2011;25:792–9.

Wong KK, Brennan F, Chesney A, Spaner DE, Gorczynski RM. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. *Cancer Res* 2012;72:4931–43.

Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltan D, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. *J Immunol* 2007;178:5595–605.

Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM. The role of CD200 in immunity to B cell lymphoma. *J Leukoc Biol* 2010;88:361–72.

Turtle CJ, Hay KA, Hanafi LA, Li D, Chervin S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibritinib. *J Clin Oncol* 2017;35:3010–20.

Pavletic SZ, Kumar S, Mohty M, De Lima M, Foran JM, Pasquini M, et al. NCI first international workshop on the biology, prevention, treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. *Blood Marrow Transplant* 2010;16:871–90.

Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. *Expert Opin Biol Ther* 2011;11:473–87.

Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. *Best Pract Res Clin Haematol* 2008;21:205–22.

Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukemia with no response to donor lymphocyte infusions after haploidentical hematopoietic stem cell transplantation. *Br J Haematol* 2017;179:598–605.

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an Anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. *J Clin Oncol* 2016;34:1112–21.

Zhu Y, Tan Y, Ou R, Zhong Q, Zheng L, Du Y, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. *Eur J Haematol* 2016;96:389–96.

Turtle CJ, Hanafi LA, Berger C, Gooley T, Chaney C, Cherian C, et al. Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. *J Clin Oncol* 2016;34:102.

Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. *Annu Rev Med* 2016;67:165–83.

Salvado B, Ramos CA, Liu E, Mims MP, Keating MI, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Invest* 2011;121:1822–6.

Bentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. *Clin Cancer Res* 2007;13:5426–35.

Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* 2004;18:676–84.

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased interleukin-2 and cytokine secretion in vivo. *Mol Ther* 2009;17:1453–64.

Schuster SJ, Svoboda J, Dwiwody Nasta S, Porter DL, Chong EA, Mahnke Y, et al. Phase iiia trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. *Blood* 2014;124:3087.

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010;116:4099–102.

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Marie I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2012;119:2709–20.

Kochenderfer JN, Somerville R, Lu L, Iwamoto A, Yang JC, Klebanoff C, et al. Anti-CD19 CAR-T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. *Blood* 2014;124:550.

Turtle CJ, Berger C, Sommermeyer D, Hanafi LA, Pender B, Robinson EM, et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. *Blood* 2015;126:184.

Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. *Clin Immunol* 2014;155:160–75.

Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. *Blood* 2008;112:2261–71.

Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. *Nature* 1982;299:65–7.

Stein H, Mason DY, Gerdes J, O’Connor N, Waincoat J, Pillesgen G, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood* 1985;66:848–58.

Pierce JM, Mehta A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. *Expert Rev Hematol* 2017;10:29–37.

Horie R, Watanabe T. CD30: expression and function in health and disease. *Semin Immunol* 1998;10:457–70.

Falini B, Pileri S, Pizzolo G, Dùrkop H, Flenghi L, Stupè F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. *Blood* 1995;85:1–14.

Onca AS, Jazireh AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphomas. *Am J Cancer Res* 2016;6:403–24.

Ramos CA, Salvado B, Liu E, Gee AP, Mei Z, Grillage BJ, et al. Clinical responses in patients infused with T lymphocytes redirected to target k-light immunoglobulin chain. *Blood* 2013;122:506.

The International Myeloma Working Group. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol* 2003;121:749–57.
90. Chung C. Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy. *Pharmacochemistry* 2017;37:129–43.

91. Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M. Magic year for multiple myeloma: takeaways from the ASH 2015 annual meeting. *Oncotarget* 2017;8:10748–59.

92. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. *Lancet* 1996;347:800–1.

93. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. *Blood* 1996;87:1196–8.

94. Garfall AL, Mauw MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. *N Engl J Med* 2015;373:1040–7.

95. Hajek R, Okubote SA, Svavchova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. *Br J Haematol* 2013;163:551–64.

96. Atanackovic D, Radhakrishnan SV, Bhaward N, Luettens T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. *Br J Haematol* 2016;172:685–98.

97. Kocoglu M, Badros A. The role of immunotherapy in multiple myeloma. *Pharmaceuticals* 2016;9:3.

98. Al-Hujaily EM, Oldham RA, Hari P, Medin JA. Development of novel immunotherapies for multiple myeloma. *Int J Mol Sci* 2016;17:1506.

99. O’Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. *Am J Clin Pathol* 2004;121:254–63.

100. Kambham N, Kong C, Longacre TA, Natkunan Y. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1754 cases. *Appl Immunohistochem Mol Morphol* 2005;13:304–10.

101. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. *Am J Clin Pathol* 2004;121:482–8.

102. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen (BCMA) expression in the diagnosis and management of cytokine release syndrome. *Blood* 2014;124:188–95.

103. Wei G, Ding L, Wang J, Hu Y, Huang H. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. *Exp Hematol Oncol* 2017;6:110.

104. Whilding LM, Maher J. CAR-T-cell immunotherapy: the path from the by-road to the freeway?. *Mol Oncol* 2015;9:1994–2018.

105. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov* 2017;7:1404–19.

106. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR-T-cell therapy. *Mol Ther Oncolytics* 2016;3:16011.

107. Batlevi CL, Matsuki E, Brentjens RJ, Byrd JC. Antigen evasion from CAR therapy. *Mol Ther Nucleic Acids* 2013;2:e105.

108. Ruella M, Barrett DM, Kenderian SS, Sheshova O, Hofmann TJ, Perazzelli J, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *J Clin Invest* 2016;126:3814–26.

109. Wang Z, Guo Y, Han W. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. *Protein Cell* 2017;8:896–925.

110. Jackson HJ, Brentjens RJ. Overcoming antigen escape with CAR-T-cell therapy. *Cancer Discov* 2015;5:1238–40.

111. Coen AD, Garfall AL, Staudmer EA, Lacey SF, Lancaster E, Vogl DT, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. *Blood* 2016;128:1147.
132. Bartee MY, Dunlap KM, Bartee E. Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells. *Clin Lymphoma Myeloma Leuk* 2016;16:203–12.

133. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. *Hum Gene Ther* 2010;21:179–90.

134. Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. *Br J Haematol* 2007;137:133–41.

135. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. *Leukemia* 2008;22:361–9.

136. Esfandyari T, Tefferi A, Szmidt A, Alain T, Zwolak P, Lasho T, et al. Transcription factors downstream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. *Mol Oncol* 2009;3:464–8.

137. Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. *Blood* 2014;123:1327–35.

138. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. *Cancer Res* 2014;74:5195–205.

139. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR-T cells against metastatic head and neck cancer. *Mol Ther* 2017;25:2440–51.

140. Geyer MB, Brentjens RJ. Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. *Cytotherapy* 2016;18:1393–409.

141. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. *Blood* 2007;109:4698–4707.

142. Heiblig M, Elhamri M, Michallet M, Thomas X. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors. *World J Stem Cells* 2015;7:1022–38.

143. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med* 2011;365:1673–83.

144. Juillerat A, Marechal A, Filhol JM, Valton J, Ducrert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. *Sci Rep* 2016;6:18950.

145. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. *Proc Natl Acad Sci U S A* 2016;113: E450–8.